The abstract is read at the publisher; the summary is JClub's.
Global estimates of metabolic dysfunction-associated steatotic liver disease (MASLD) are substantial and vary widely across populations, with the fastest-changing burden in sub-Saharan Africa and Asia Pacific.
- Why it matters: The growing obesity and type 2 diabetes epidemics make MASLD’s prevalence, complications, and life-expectancy impact a major healthcare and patient burden, yet estimates differ by region and population.
- What they did: This review synthesizes global MASLD burden estimates, including prevalence, incidence, disability from complications, and reduced life expectancy, and examines drivers of variability such as social determinants of health.
- The result: The analysis highlights where epidemiological transition and inequities may shape MASLD burden and points to opportunities to improve equity in prevention, diagnosis, and treatment worldwide.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.